BARD1 LAUNCHES ITS RUO EXO-NET® PRODUCT

- **BARD1 will launch its first Molecular NET product, EXO-NET®, for research use at the ISEV Annual Meeting 18-21 May 2021**
- **EXO-NET® is a next-generation technology that allows fast, accurate and scalable capture of exosomes from any biological sample**
- **Exosomes are nanoparticles that are released from most cells and are a current focus of intense global research for multiple diagnostic and therapeutic applications**
- **The ISEV2021 conference is the premier international exosome conference**

Melbourne, Australia, 18 May 2021: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) is pleased to announce that the Company's first product based on its Molecular NET technology, EXO-NET®, will be launched at the virtual International Society of Extracellular Vesicles (ISEV) Annual Meeting from 18-21 May 2021.

EXO-NET® is a next-generation exosome isolation and purification tool, available for research use only (RUO). EXO-NET® captures exosomes in a fast, accurate and scalable manner from any biological sample including blood, urine and saliva. EXO-NET® is now available for sale to academia and industry for the first time at the ISEV2021 and can be ordered from BARD1 at www.exo-net.com. Watch our video here explaining how EXO-NET® captures exosomes in less than 15 minutes.

Exosomes are small extracellular vesicles (nanoparticles) that are released from most cells, including cancer cells, into body fluids and have important functions in cellular communication. Exosomes have enormous clinical and commercial potential in the diagnosis and treatment of numerous diseases.

Launching RUO EXO-NET® into the research market has the potential to embed EXO-NET® into the discovery, research and development phases for multiple exosome-based diagnostic and therapeutic applications, leading to commercial sales and licensing opportunities.

According to Grand View Research, the global exosome market including research tools, diagnostics and therapeutics is expected to reach US$2.3 billion by 2030, growing at over 18% per annum.[1]

The ISEV2021 conference showcases the best in extracellular vesicle (EV) science, covering all aspects of fundamental, translational and clinical research, disseminating cutting-edge developments in EV research. ISEV2021 brings together scientists from academic, clinics, and industry, who have a common goal of understanding EVs and applying this knowledge for societal and economic benefit.

BARD1 Chief Scientific Officer, Dr Peter French, said: "We are very excited to launch EXO-NET® to the global exosome research market at the ISEV2021 conference. EXO-NET solves the sample preparation problems encountered using traditional exosome capture methods by providing fast, accurate and scalable capture of exosomes from any liquid sample. Furthermore, the potential of this technology is largely untapped, as only EXO-NET® can be customised for the capture of target exosome sub-populations for a range of commercial diagnostic and therapeutic applications. This is becoming a major focus of exosome research and development."

BARD1 CEO, Dr Leearne Hinch, said: "This is a major milestone in BARD1's commercial development of its Molecular NET technology. The exosome field is rapidly growing across research, diagnostic and therapeutic applications for cancer, inflammatory disease and wound healing. BARD1 intends to position itself as a leader in the exosomes field. Launch of RUO EXO-NET® as an exosome capture tool is the first step in the commercialisation of BARD1's exosome-based product portfolio. BARD1 intends to leverage its next-generation EXO-NET® technology to build a pipeline of exosome-based diagnostics for multiple indications. The Company will also seek to partner with industry leaders to develop exosome therapeutic manufacturing solutions, and companion diagnostics for new immunotherapeutics."

[1] Grand View Research. Exosomes Market Size to Reach $2.28 Billion by 2030. Jan 2018. Available: https://www.grandviewresearch.com/press-release/global-exosomes-market

BARD1 R&D Manager and EXO-NET® inventor, Dr Emily Stein said: “This is the culmination of many years of development of EXO-NET®. It was conceived to address the cumbersome traditional approaches to exosome isolation based on ultracentrifugation and size exclusion. BARD1 has helped me realise the dream of bringing a commercial exosome isolation product to market that is really quick and easy for researchers to use and obtain great results.”

There is increasing interest in exosomes because they contain important molecules such as DNA, RNA, proteins and lipids that enable exosomes to carry out a range of vital functions in the body including stem cell-like repair. Exosomes also provide valuable clues to a person’s health as they contain molecules from the host cells that can be used for **diagnosis** of diseases, including cancer, metabolic, inflammatory disease, cardiac disease and neurodegenerative conditions such as Alzheimer’s disease.

Additionally, exosomes also have potential **therapeutic** applications, with over 20 biopharma companies currently researching the use of exosomes to treat numerous diseases and 112 clinical studies investigating the use of exosomes as a treatment for various diseases.[2]

A critical step in the successful development of commercially viable exosome diagnostics and therapeutics is the isolation and purification of exosomes using consistent, reproducible and scalable methods. Existing methods used to isolate or purify exosomes from body fluids are time consuming, not readily scalable and are frequently contaminated with non-exosome particles. EXO-NET® addresses the current exosome purification shortfalls, potentially enabling exosomes to become a “game-changer” for diagnosing and treating multiple diseases.

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch
CEO
E leearne@bard1.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@bard1.com
M +61 417 203 021

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising best-in-class diagnostic solutions based on its BARD1, SubB2M, and Molecular NETs platforms for healthcare professionals and patients. The cancer diagnostics portfolio includes the commercialised hTERT test used as an adjunct to urine cytology and development-stage tests for ovarian, breast, prostate and pancreatic cancers. The Company is also commercialising its Molecular NETs platform for sample preparation and has launched its first proprietary EXO-NET® exosome capture tool for use in research for exosome-based diagnostics and therapeutics. For more information on BARD1 and EXO-NET, visit www.bard1.com and www.exo-net.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain ‘forward-looking statements’ within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as ‘may,’ ‘should,’ ‘expect,’ ‘anticipate,’ ‘estimate,’ ‘scheduled’ or ‘continue’ or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.

[2] Clinicaltrials.gov